These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
500 related articles for article (PubMed ID: 26350955)
1. In-parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance. Porpiglia F; Cantiello F; De Luca S; Manfredi M; Veltri A; Russo F; Sottile A; Damiano R BJU Int; 2016 Oct; 118(4):527-34. PubMed ID: 26350955 [TBL] [Abstract][Full Text] [Related]
2. PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance. Cantiello F; Russo GI; Cicione A; Ferro M; Cimino S; Favilla V; PerdonĂ S; De Cobelli O; Magno C; Morgia G; Damiano R World J Urol; 2016 Apr; 34(4):485-93. PubMed ID: 26194612 [TBL] [Abstract][Full Text] [Related]
3. Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy. Cantiello F; Russo GI; Ferro M; Cicione A; Cimino S; Favilla V; PerdonĂ S; Bottero D; Terracciano D; De Cobelli O; Morgia G; Damiano R Urol Oncol; 2015 Apr; 33(4):163.e15-23. PubMed ID: 25575715 [TBL] [Abstract][Full Text] [Related]
4. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance. Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389 [TBL] [Abstract][Full Text] [Related]
5. Multiparametric magnetic resonance imaging and active surveillance: How to better select insignificant prostate cancer? Porpiglia F; Cantiello F; De Luca S; De Pascale A; Manfredi M; Mele F; Bollito E; Cirillo S; Damiano R; Russo F Int J Urol; 2016 Sep; 23(9):752-7. PubMed ID: 27277398 [TBL] [Abstract][Full Text] [Related]
6. Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine. Ferro M; Lucarelli G; Bruzzese D; PerdonĂ S; Mazzarella C; Perruolo G; Marino A; Cosimato V; Giorgio E; Tagliamonte V; Bottero D; De Cobelli O; Terracciano D Anticancer Res; 2015 Feb; 35(2):1017-23. PubMed ID: 25667489 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the accuracy of multiparametric magnetic resonance imaging (mpMRI) results with the final pathology findings for radical prostatectomy specimens in the detection of prostate cancer. Lee CH; Ku JY; Park WY; Lee NK; Ha HK Asia Pac J Clin Oncol; 2019 Apr; 15(2):e20-e27. PubMed ID: 29920966 [TBL] [Abstract][Full Text] [Related]
8. Integration and Diagnostic Accuracy of 3T Nonendorectal coil Prostate Magnetic Resonance Imaging in the Context of Active Surveillance. Curci NE; Lane BR; Shankar PR; Noyes SL; Moriarity AK; Kubat A; Brede C; Montgomery JS; Auffenberg GB; Miller DC; Montie JE; George AK; Davenport MS Urology; 2018 Jun; 116():137-143. PubMed ID: 29653121 [TBL] [Abstract][Full Text] [Related]
9. The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy? Porpiglia F; Russo F; Manfredi M; Mele F; Fiori C; Bollito E; Papotti M; Molineris I; Passera R; Regge D J Urol; 2014 Jul; 192(1):60-6. PubMed ID: 24518780 [TBL] [Abstract][Full Text] [Related]
10. Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy. Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Pennisi M; Morgia G Scand J Urol; 2017 Aug; 51(4):260-263. PubMed ID: 28513296 [TBL] [Abstract][Full Text] [Related]
11. Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance. Schwen ZR; Mamawala M; Tosoian JJ; Druskin SC; Ross AE; Sokoll LJ; Epstein JI; Carter HB; Gorin MA; Pavlovich CP BJU Int; 2020 Sep; 126(3):373-378. PubMed ID: 32367635 [TBL] [Abstract][Full Text] [Related]
12. Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen. Radtke JP; Schwab C; Wolf MB; Freitag MT; Alt CD; Kesch C; Popeneciu IV; Huettenbrink C; Gasch C; Klein T; Bonekamp D; Duensing S; Roth W; Schueler S; Stock C; Schlemmer HP; Roethke M; Hohenfellner M; Hadaschik BA Eur Urol; 2016 Nov; 70(5):846-853. PubMed ID: 26810346 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the accuracy of multiparametric MRI for predicting prostate cancer pathology and tumour staging in the real world: an multicentre study. Kam J; Yuminaga Y; Krelle M; Gavin D; Koschel S; Aluwihare K; Sutherland T; Skinner S; Brennan J; Wong LM; Louie-Johnsun M BJU Int; 2019 Aug; 124(2):297-301. PubMed ID: 30714285 [TBL] [Abstract][Full Text] [Related]
14. Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol. Luzzago S; Musi G; Catellani M; Russo A; Di Trapani E; Mistretta FA; Bianchi R; Cozzi G; Conti A; Pricolo P; Ferro M; Matei DV; Mirone V; Petralia G; de Cobelli O Urol Int; 2018; 101(1):56-64. PubMed ID: 29734177 [TBL] [Abstract][Full Text] [Related]
15. Prostate cancer gene 3 (PCA3) is of additional predictive value in patients with PI-RADS grade III (intermediate) lesions in the MR-guided re-biopsy setting for prostate cancer. Kaufmann S; Bedke J; Gatidis S; Hennenlotter J; Kramer U; Notohamiprodjo M; Nikolaou K; Stenzl A; Kruck S World J Urol; 2016 Apr; 34(4):509-15. PubMed ID: 26267808 [TBL] [Abstract][Full Text] [Related]
16. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169 [TBL] [Abstract][Full Text] [Related]
17. A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection. Hendriks RJ; van der Leest MMG; Dijkstra S; Barentsz JO; Van Criekinge W; Hulsbergen-van de Kaa CA; Schalken JA; Mulders PFA; van Oort IM Prostate; 2017 Oct; 77(14):1401-1407. PubMed ID: 28853167 [TBL] [Abstract][Full Text] [Related]
18. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. Scattoni V; Lazzeri M; Lughezzani G; De Luca S; Passera R; Bollito E; Randone D; Abdollah F; Capitanio U; Larcher A; Lista G; Gadda GM; Bini V; Montorsi F; Guazzoni G J Urol; 2013 Aug; 190(2):496-501. PubMed ID: 23466239 [TBL] [Abstract][Full Text] [Related]
19. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification? Roscigno M; Stabile A; Lughezzani G; Pepe P; Galosi AB; Naselli A; Naspro R; Nicolai M; La Croce G; Aljoulani M; Perugini G; Guazzoni G; Montorsi F; Balzarini L; Sironi S; Da Pozzo LF Clin Genitourin Cancer; 2020 Dec; 18(6):e698-e704. PubMed ID: 32493676 [TBL] [Abstract][Full Text] [Related]
20. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings. Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]